首页> 外文期刊>Cell biochemistry and biophysics >Efficacy and Safety of Parecoxib/Phloroglucinol Combination Therapy Versus Parecoxib Monotherapy for Acute Renal Colic: A Randomized, Double-Blind Clinical Trial
【24h】

Efficacy and Safety of Parecoxib/Phloroglucinol Combination Therapy Versus Parecoxib Monotherapy for Acute Renal Colic: A Randomized, Double-Blind Clinical Trial

机译:帕瑞昔布/间苯三酚联合疗法与帕瑞昔布单药治疗急性肾绞痛的疗效和安全性:一项随机,双盲临床试验

获取原文
获取原文并翻译 | 示例
           

摘要

To investigate whether the addition of phloroglucinol to parecoxib could improve the efficacy in patients with acute renal colic. Patients of acute renal colic were randomly allocated to receive intravenous Parecoxib 40 mg plus placebo or Parecoxib 40 mg plus phloroglucinol 80 mg, respectively. Pain intensity was recorded using a visual analog scale (VAS) before drug administration and 5, 15, 30, 60, and 120 min after treatment start. The primary outcome was the mean pain intensity difference (PID) at each checkpoint and the effectiveness of drugs (≥50 % decrease in VAS score at the end checkpoint). The need for rescue analgesics and the incidence of adverse effects were considered as secondary outcome of the study. Among 236 patients enrolled in the study, 119 patients received intravenous parecoxib plus placebo and 114 patients received intravenous parecoxib plus phloroglucinol, the remaining 3 patients given up treatment. Baseline demographics were similar between two groups. There are significant differences in the PID at 15 and 30 min between two groups (P 15 min = 0.011, P 30 min = 0.013). Rescue analgesics were required by 17 patients (14.3 %) receiving parecoxib, 7 patients (6.1 %) receiving parecoxib plus phloroglucinol (P = 0.041). There were no differences in PID at other checkpoints between two groups, as well as in the incidence of adverse events and the drug effectiveness. Parecoxib in combination with phloroglucinol for acute renal colic has a faster action, also reduces the demand of rescue analgesics.
机译:为了研究在帕瑞昔布中添加间苯三酚是否可以提高急性肾绞痛患者的疗效。急性肾绞痛患者被随机分配接受静脉注射帕瑞昔布40 mg加安慰剂或帕瑞昔布40 mg加间苯三酚80 mg。在给药前和治疗开始后5、15、30、60和120分钟,使用视觉模拟量表(VAS)记录疼痛强度。主要结局是每个检查点的平均疼痛强度差异(PID)和药物的有效性(终点检查点的VAS评分降低≥50%)。急救镇痛药的需要和不良反应的发生被认为是该研究的次要结果。在该研究的236位患者中,有119位患者接受了帕瑞昔布静脉联合安慰剂治疗,有114位患者接受了帕瑞昔布静脉联合间苯三酚治疗,其余3例患者放弃了治疗。两组之间的基线人口统计数据相似。两组在15和30分钟时的PID差异显着(P 15分钟= 0.011,P 30分钟= 0.013)。接受帕瑞昔布的17例患者(14.3%),帕瑞昔布加间苯三酚7例(6.1%)需要抢救镇痛剂(P = 0.041)。两组之间其他检查点的PID,不良事件发生率和药物有效性均无差异。帕瑞昔布与间苯三酚联合用于急性肾绞痛具有较快的作用,也减少了急救镇痛药的需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号